

Ilw

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
25429/9

In Re Application Of: Jackson et al.

Application No.

Filing Date

Examiner

Customer No.

Group Art Unit

Confirmation No.

10/731,550

December 9, 2003

Terra C. Gibbs

21710

1635

4567

Title: **DOPAMINERGIC NERUONS DIFFERENTIATED FROM EMBRYONIC CELLS FOR TREATING NEURODEGENERATIVE DISEASES**

Address to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.

25429/9

In Re Application of: Isacson et al.

OCT 21 2005

Application No.

10/731,550

Filing Date

December 9, 2003

Examiner

Terra C. Gibbs

Customer No.

21710

Group Art Unit

1635

Confirmation No.

4567

Title: DOPAMINERGIC NERUONS DIFFERENTIATED FROM EMBRYONIC CELLS FOR TREATING NEURODEGENERATIVE DISEASES**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 50-0369 as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**Certificate of Transmission by Facsimile***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

10/18/05

(Date)

Suman SU

Signature of Person Mailing Correspondence

Seema M. Shah

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Dated: 10/18/05

Signature

Anthony C. Kuhlmann, Ph.D., Reg. No. 57,147

Attorney for Applicant(s)

Brown Rudnick Berlack Israels LLP

One Financial Center, Box IP


Boston, MA 02111

Tel: (617) 856-8349

Fax: (617) 856-8201

Email: ip@brownrudnick.com

CC:

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT 				ATTY DOCKET NO. 25429/9		SERIAL NO. 10/731,550	
				APPLICANT(S): Isacson et al.			
				FILING DATE: December 9, 2003		ART UNIT: 1635	
UNITED STATES PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	INVENTOR	CLASS	SUB CLASS	FIL. DATE IF APPR
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN Y/N
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)							
	Sakurada et al. "Nurr1, an orphan nuclear receptor, is a transcriptional activator of endogenous tyrosine hydroxylase in neural progenitor cells derived from the adult brain." Development, 1999 Vol. 126:4017-4026.						
	Bjorklund et al. "Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model." Proc. Natl. Acad. Sci., 2002 Vol. 99:2344-2349						
	Ramsden et al. "The aetiology of idiopathic Parkinson's disease." Journal of Clinical Pathology: Molecular Pathology; 2001 Vol. 54:369-380.						
	Attisano et al. Signal Transduction by the TGF-beta Superfamily. Science, 2002 Vol. 296:1646-1647.						
Examiner:					Date:		